Active Ingredient History
Bortezomib is the therapeutic proteasome inhibitor. First, which is tested in humans. The boron atom in bortezomib binds the catalytic site of the 26S proteasome with high affinity and specificity. Bortezomib is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. The 26S proteasome degrades various proteins critical to cancer cell survival, such as cyclins, tumor suppressors, BCL-2, and cyclin-dependent kinase inhibitors. Inhibition of these degradations sensitizes cells to apoptosis. Bortezomib is a potent inhibitor of 26S proteasome, which sensitizes activity in dividing multiple myeloma and leukemic cells, thus inducing apoptosis. Most commonly reported adverse reactions (incidence ≥30%) in clinical studies include asthenic conditions, diarrhea, nausea, constipation, peripheral neuropathy, vomiting, pyrexia, thrombocytopenia, psychiatric disorders, anorexia and decreased appetite, neutropenia, neuralgia, leukopenia and anemia. Co-administration of ketoconazole, a potent CYP3A inhibitor, increased the exposure of bortezomib. Co-administration of melphalan-prednisone increased the exposure of bortezomib. However, this increase is unlikely to be clinically relevant. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma, Bronchiolo-Alveolar (Phase 2)
Adenocarcinoma of Lung (Phase 2)
Adenoma, Islet Cell (Phase 2)
Agglutination (Phase 2)
Allergy and Immunology (Phase 4)
Amyloidosis (Phase 3)
Anaplasia (Phase 2)
Anemia (Phase 1)
Anemia, Hemolytic, Autoimmune (Phase 2)
Anemia, Refractory (Phase 1)
Anemia, Sickle Cell (Phase 1)
Arthritis, Rheumatoid (Phase 2)
Astrocytoma (Phase 1)
Atrophy (Phase 1)
Autografts (Early Phase 1)
Autoimmune Diseases (Phase 2)
beta-Thalassemia (Phase 1)
Bile Duct Neoplasms (Phase 2)
Blood Protein Disorders (Phase 2)
Bone Marrow Transplantation (Phase 2)
Bortezomib (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Brenner Tumor (Phase 1)
Bronchiolitis Obliterans (Phase 2)
Burkitt Lymphoma (Phase 2)
Carcinoid Tumor (Phase 1)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Verrucous (Phase 2)
Castleman Disease (Phase 2)
Central Nervous System Neoplasms (Phase 1)
Cholangiocarcinoma (Phase 3)
Choriocarcinoma (Phase 1)
Choroid Plexus Neoplasms (Phase 1)
Chromosome Aberrations (Phase 1)
Colonic Neoplasms (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Craniopharyngioma (Phase 1)
Cyclophosphamide (Phase 2)
Dexamethasone (Phase 2)
DNA Mismatch Repair (Phase 1)
Drug Evaluation (Phase 4)
Ependymoma (Phase 1)
Epstein-Barr Virus Infections (Phase 2)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 1)
Gallbladder Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 2)
Germinoma (Phase 1)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Glomerulonephritis, IGA (Phase 4)
Glycogen Storage Disease Type II (Phase 4)
Graft Rejection (Phase 2)
Graft vs Host Disease (Phase 2)
Granulocyte Colony-Stimulating Factor (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Heart Transplantation (Phase 2)
Hematologic Diseases (Phase 2)
Hematologic Neoplasms (Phase 4)
Hematopoietic Stem Cell Transplantation (Phase 3)
Hematuria (Phase 4)
Hemophilia A (Phase 2)
Herpesvirus 8, Human (Phase 2)
HIV (Phase 2)
HIV Infections (Phase 1)
Hodgkin Disease (Phase 2)
Immunoglobulin Light-chain Amyloidosis (Phase 3)
Immunoglobulin Light Chains (Phase 3)
Intestinal Neoplasms (Phase 2)
Intraocular Lymphoma (Phase 1)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 2)
Kidney Neoplasms (Phase 2)
Kidney Transplantation (Phase 4)
Laryngeal Neoplasms (Phase 1)
Leukemia (Phase 3)
Leukemia, B-Cell (Phase 2)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Eosinophilic, Acute (Phase 2)
Leukemia, Large Granular Lymphocytic (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Monocytic, Acute (Phase 2)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Leukemia, Plasma Cell (Phase 2)
Leukemia, Prolymphocytic (Phase 1)
Leukemia, T-Cell (Phase 2)
Liver Diseases (Phase 1)
Liver Neoplasms (Phase 2)
Lung Diseases, Interstitial (Phase 2)
Lung Neoplasms (Phase 2)
Lupus Erythematosus, Systemic (Phase 2)
Lupus Nephritis (Phase 4)
Lymphoma (Phase 3)
Lymphoma, AIDS-Related (Phase 1)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 3)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Lymphomatoid Granulomatosis (Phase 1)
Lymphoproliferative Disorders (Phase 2)
Medulloblastoma (Phase 1)
Melanoma (Phase 2)
Meningioma (Phase 1)
Mesothelioma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Mouth Neoplasms (Phase 1)
Myasthenia Gravis (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasm, Residual (Phase 4)
Neoplasms ()
Neoplasms by Histologic Type (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 1)
Neoplasms, Plasma Cell (Phase 2)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors (Phase 1)
Neuromyelitis Optica (Phase 2)
Oligodendroglioma (Phase 1)
Oncogenes (Phase 2)
Organ Transplantation (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Paraproteinemias (Phase 2)
Parathyroid Neoplasms (Phase 1)
Patient Participation (Phase 1/Phase 2)
Pharyngeal Neoplasms (Phase 1)
Plasmablastic Lymphoma (Phase 2)
Plasmacytoma (Phase 3)
Pleural Effusion, Malignant (Phase 2)
Precancerous Conditions (Phase 1)
Primary Immunodeficiency Diseases (Phase 2)
Primary Myelofibrosis (Phase 2)
Prostatic Neoplasms (Phase 2)
Proteinuria (Phase 4)
Purpura (Phase 4)
Purpura, Thrombocytopenic, Idiopathic (Phase 3)
Rectal Neoplasms (Phase 1/Phase 2)
Recurrence (Phase 1/Phase 2)
Renal Insufficiency (Phase 2)
Renal Insufficiency, Chronic (Phase 4)
Safety (Phase 4)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Kaposi (Phase 1)
Sarcoma, Myeloid (Phase 3)
Scleroderma, Systemic (Phase 2)
Sezary Syndrome (Phase 1)
Small Cell Lung Carcinoma (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Squamous Intraepithelial Lesions (Phase 2)
Stomach Neoplasms (Phase 2)
Therapeutics (Phase 1/Phase 2)
Thrombocytopenia (Phase 2)
Thyroid Neoplasms (Phase 2)
Tongue Neoplasms (Phase 2)
Transplantation (Phase 1)
Transplantation, Homologous (Phase 1)
Uremia (Phase 1/Phase 2)
Ureteral Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 4)
Wilms Tumor (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
